Hematology, Transfusion and Cell Therapy最新文献

{"title":"False-positive test results: prevalence, time trends, and factors associated with false-positive serological markers in blood donation screening","authors":"Lucas Kallas-Silva,&nbsp;Leandro Dinalli dos Santos,&nbsp;Valeria de Freitas Dutra,&nbsp;Jose Mauro Kutner,&nbsp;Carolina Bonet-Bub","doi":"10.1016/j.htct.2026.106499","DOIUrl":"10.1016/j.htct.2026.106499","url":null,"abstract":"<div><h3>Background and Objectives</h3><div>False-positive serological results in blood donation screening may arise from antibody cross-reactivity, limitations in assay specificity, or low-level reactivity during early-stage infections, ultimately leading to donor deferral and the discard of viable blood units. This study evaluated the prevalence, time trends, and demographic factors associated with false-positive serologic screening results for transfusion-transmissible infections in a Brazilian blood center.</div></div><div><h3>Materials and Methods</h3><div>A cross-sectional study was conducted including all blood donations collected between 2013 and 2022 at a private blood center in São Paulo, Brazil. Donations were screened with serologic tests for syphilis, human immunodeficiency virus, hepatitis B virus, and hepatitis C virus. Reactive samples underwent confirmatory testing, where a false-positive result was defined as an initially reactive screening assay followed by a nonreactive confirmatory test. Associations between demographic variables and false-positive or true-positive results compared to true negative results were analyzed using multivariable Poisson regression.</div></div><div><h3>Results</h3><div>A total of 129,166 donors were included. Most donors (98.7%) had nonreactive results for all serologic tests. Reactive screening results were observed in 0.5% of donations for both syphilis and hepatitis B virus, 0.2% for hepatitis C virus, and 0.1% for human immunodeficiency virus. False positivity occurred more frequently for human immunodeficiency virus (92.0%) and hepatitis C virus (72.7%). Older age, lower education levels, and first-time donation were associated with false-positive results, whereas male sex, non-white race/skin color, lower education levels, and being single or divorced were associated with true-positive status.</div></div><div><h3>Conclusion</h3><div>False-positive results were more frequent among first-time and less-educated donors. This study found no consistent overlap between demographic factors associated with false positivity and true positivity. This suggests that false positivity mainly occurs by chance or from antibody cross-reactivity.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106499"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13393157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148498526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of trauma patients requiring massive transfusion protocol activation: A retrospective cohort study at a tertiary hospital in Malaysia","authors":"Mohd Redzuan Abdullah,&nbsp;Thaenujah Nair Ramachandran,&nbsp;Aidil Noor Adnan,&nbsp;Azian Md Yacob,&nbsp;Siti Fatimah Mohamed Kamaruzzaman,&nbsp;Ahmad Zakimi Abdullah,&nbsp;Nurul Aiman Addenan,&nbsp;Maryam Sumaiya Ahmad Termizi,&nbsp;Joan Gan Cheau Yan,&nbsp;Seniyah Md Sikin,&nbsp;Low Wen Ying,&nbsp;Azarina Zakaria,&nbsp;Wagner Loo Cheng Poh,&nbsp;Zulkifli Hassan,&nbsp;Alex Lim Tat Leong,&nbsp;Siti Aisah Hassan","doi":"10.1016/j.htct.2026.106489","DOIUrl":"10.1016/j.htct.2026.106489","url":null,"abstract":"<div><h3>Background</h3><div>Trauma is one of the main causes of morbidity and mortality worldwide. Understanding the factors affecting the survivability of trauma patients is crucial, especially those requiring the activation of the massive transfusion protocol. This study aimed to determine survival outcomes and identify factors associated with mortality among trauma patients requiring massive transfusion activation.</div></div><div><h3>Materials and methods</h3><div>This was a retrospective cohort study of 71 trauma patients who required activation of the massive transfusion protocol. The trauma patients were divided into Survivor (n = 41) and Non-survivor groups (n = 30). The activation criteria for massive transfusions were an assessment of blood consumption score ≥2.</div></div><div><h3>Results</h3><div>The hospital mortality rate for trauma patients who required activation of the massive transfusion protocol was 42.3%. Most of the patients were male (90.1%), of Malay ethnicity (49.3%), and had blood group O (40.8%). The commonest cause of trauma was road traffic accidents (84.5%). Patients with severe Glasgow Coma Scores had approximately 4.2 times higher odds of mortality compared with those with non-severe Glasgow Coma Scores (p-value = 0.014). Haemoglobin level was independently associated with outcome, with lower haemoglobin levels observed among non-survivors (adjusted odds ratio: 1.38; 95% CI: 1.03–1.85; p-value = 0.030).</div></div><div><h3>Conclusions</h3><div>The survivability of trauma patients who need massive transfusion protocol activation was associated with Glasgow Coma Score and haemoglobin level on arrival. It is crucial to determine factors that affect the survivability of trauma patients for the early identification of those at risk and to initiate prompt management and resuscitation in the future.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106489"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148341657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet counts, but not neutrophil counts, are associated with non-bleeding-related mortality in patients with hematological malignancies and post-chemotherapy febrile neutropenia","authors":"Gabriela Romantini Salioni,&nbsp;Carla Roberta Peachazepi Moraes,&nbsp;Leticia Queiroz da Silva,&nbsp;Edwin Mayr,&nbsp;Bruno Kosa Lino Duarte,&nbsp;Erich V De Paula","doi":"10.1016/j.htct.2026.106498","DOIUrl":"10.1016/j.htct.2026.106498","url":null,"abstract":"<div><h3>Introduction</h3><div>Neutrophils and platelets are key elements of the host immune response to sepsis, participating in both pathogen clearance and in sepsis-related tissue damage. Although it is widely recognized that patients with hematological malignancies and chemotherapy-induced febrile neutropenia are at increased risk of severe sepsis complications, the prognostic impact of neutrophil and platelet counts on sepsis-related outcomes remains controversial, with conflicting results regarding the magnitude of neutropenia. Moreover, to our knowledge, no studies have addressed the association of thrombocytopenia with outcomes in febrile neutropenia in patients with hematological malignancies. This study investigated the association of neutropenia and thrombocytopenia in a consecutive cohort of 113 patients with underlying hematological malignancies who were admitted to an academic tertiary hospital with chemotherapy-induced neutropenia.</div></div><div><h3>Methods</h3><div>Neutrophil and platelet counts were obtained at fever onset and 24, 48 and 72 hours thereafter.</div></div><div><h3>Results</h3><div>Neutrophil counts at the time of febrile neutropenia were not associated with sepsis-related mortality or other negative outcomes. However, a lower platelet count at fever onset was associated with non-bleeding sepsis-related mortality and the need of organ support. Moreover, the trajectories of both neutrophil and platelet counts in the first 72 hours after the onset of febrile neutropenia were also associated with negative outcomes.</div></div><div><h3>Conclusion</h3><div>These results highlight the heterogeneous role of platelets in the immune response and pave the way for studies exploring to what extent severe thrombocytopenia modulates the molecular and cellular mechanisms of post-febrile neutropenia sepsis in these patients.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106498"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylaxis of graft-versus-host-disease: Systematic evidence-based recommendations of the Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and the Brazilian society of cellular therapy and bone marrow transplantation (SBTMO)","authors":"Afonso C. Vigorito,&nbsp;Carmino A. de Souza,&nbsp;Nelson Hamerschlak,&nbsp;Vaneuza A.M. Funke,&nbsp;Maria Claudia R. Moreira,&nbsp;Adriana Seber,&nbsp;Renato Luiz Guerino Cunha,&nbsp;Wanderley Bernardo,&nbsp;Fernando B. Duarte","doi":"10.1016/j.htct.2026.106494","DOIUrl":"10.1016/j.htct.2026.106494","url":null,"abstract":"<div><div>Graft-versus-host disease, involving from 20%–80% of patients, is one of the main complications of allogeneic hematopoietic cell transplantation contributing significantly to mortality and morbidity. The methodological basis of these graft-versus-host disease prophylaxis guidelines for allogeneic hematopoietic cell transplantation, developed by the Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH) and the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO), is a review which applied the GRADE process to eleven PICO (population, intervention, comparator, and outcome) questions. These questions address graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation across various settings, including myeloablative and non-myeloablative/reduced-intensity conditioning. The scope encompasses related matched, unrelated matched or mismatched, and haploidentical donors, utilizing both bone marrow and peripheral blood as stem-cell sources. The combination of a calcineurin inhibitor (e.g., cyclosporine or tacrolimus) plus methotrexate or mycophenolate mofetil (MMF) has been the standard graft-versus-host disease prophylaxis regimen for allogeneic hematopoietic cell transplantation. The excellent results of post-transplant cyclophosphamide in haploidentical related donor hematopoietic cell transplantation have led to broader use in human leukocyte antigen-(mis)matched related and unrelated donor grafts. Sirolimus, low-dose antithymocyte globulin (4–6 mg/kg) and more recently abatacept are other drugs used. Hence, this review is meant to be a useful reference tool for clinicians who are dealing with this complex complication.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106494"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient blood management in Brazilian cardiovascular surgery: An exploratory survey of surgeons’ perceptions and reported practices","authors":"Maria Carolina Guido,&nbsp;Bianca Meneghini,&nbsp;Rosangela Monteiro,&nbsp;Matheus Moitinho,&nbsp;Carlos Manuel Brandão,&nbsp;Vinicius Nina,&nbsp;Guilherme Rabello,&nbsp;Fabio Jatene","doi":"10.1016/j.htct.2026.106500","DOIUrl":"10.1016/j.htct.2026.106500","url":null,"abstract":"<div><h3>Introduction</h3><div>Although the clinical benefits of patient blood management are internationally recognized, data regarding its implementation in Brazilian cardiovascular surgery remain limited. This study evaluated knowledge on patient blood management, reported practices, and perceived barriers among Brazilian cardiovascular surgeons.</div></div><div><h3>Methods</h3><div>This cross-sectional survey was conducted among 1,105 cardiovascular surgeons registered with the Brazilian Society of Cardiovascular Surgery. A 30-item questionnaire assessing professional characteristics, preoperative anemia management, perioperative transfusion practices, and patient blood management adoption was distributed via email. Descriptive and inferential statistical analyses were performed.</div></div><div><h3>Results</h3><div>The response rate was 19.4% (n = 205). Most respondents were male (91%) and based in the southeastern region. Preoperative anemia screening and management were heterogeneous. Thirty-one percent estimated the prevalence of preoperative anemia at 5%–15% in their institutions, and 43% reported hemoglobin testing 1–2 days before surgery. Approximately 25% routinely calculated erythrocyte mass and blood volume. Institutional transfusion risk protocols were reported by 48% of respondents, and 62% indicated standardized blood component request parameters. Antifibrinolytics and hemostatic agents were the most frequently reported coagulation strategies. Interest in patient blood management implementation was reported by 52%; perceived barriers included cultural resistance (43%), financial constraints (24%), and administrative challenges (21%). A statistically significant association was observed between geographic region and reported interest in patient blood management implementation.</div></div><div><h3>Conclusion</h3><div>Patient blood management implementation was reported as heterogeneous across institutions. Respondents identified cultural, economic, and structural barriers to patient blood management implementation. These findings reflect surgeons’ self-reported perceptions and should be interpreted within the limitations of a cross-sectional survey with limited regional representativeness.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106500"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13393440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding BCR::ABL1 kinase domain mutations in chronic myeloid leukemia: Implications for tyrosine kinase inhibitor resistance in a South Asian population","authors":"Fatima Sharif,&nbsp;Rafia Mahmood,&nbsp;Maimoona Roghani,&nbsp;Sikandar Hayat Khan,&nbsp;Ibrahim Khan","doi":"10.1016/j.htct.2026.106502","DOIUrl":"10.1016/j.htct.2026.106502","url":null,"abstract":"<div><h3>Introduction</h3><div>Treatment resistance has become increasingly common in patients with chronic myeloid leukemia. Lack of response to tyrosine kinase inhibitors is associated with mutations in the <em>BCR</em>::<em>ABL1</em> kinase domain. This study aims to report the frequency and types of <em>BCR</em>::<em>ABL1</em> kinase domain mutations in Pakistani chronic myeloid leukemia patients.</div></div><div><h3>Materials and methods</h3><div>This prospective study was conducted from January to June 2025 at the Armed Forces Institute of Pathology in Pakistan. It included adult patients with chronic myeloid leukemia who were non-responsive to treatment based on molecular, hematological, and clinical criteria. Allele-specific real-time polymerase chain reaction was performed to detect four kinase domain mutations: T315I, E255V, E255K and Y253H. Data was analyzed using IBM SPSS v23.</div></div><div><h3>Results</h3><div>The mean age of the 133 treatment-resistant chronic myeloid leukemia patients included in the study was 47.3 ± 13.6 years. The majority of cases (62.4%) were male and 79 (59.4%) patients were currently on imatinib therapy. The median <em>BCR</em>::<em>ABL1</em> level, as measured by quantitative polymerase chain reaction, was 30.73% (range: 1.17–100%) International Scale. <em>BCR</em>::<em>ABL1</em> kinase domain mutations were detected in 57 (42.9%) patients. E255K was the most common mutation detected in 45 (33.8%) cases, followed by E255V in 11 (8.3%), T315I in 1 (0.8%) and the Y253H mutation in 1 (0.8%) patient. The presence of kinase domain mutations was significantly associated with higher total leucocyte count (<em>p</em> = 0.002), while the E255K mutation was significantly associated with blast crisis (<em>p</em> = 0.048).</div></div><div><h3>Conclusion</h3><div>This study revealed a high prevalence of <em>BCR</em>::<em>ABL1</em> kinase domain mutations in Pakistani chronic myeloid leukemia patients. E255K, the most frequently detected mutation, was significantly associated with blast crisis. These findings underscore the significance of molecular testing for personalized treatment.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106502"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent mortality risk of plasma transfusion in critically ill patients","authors":"Min Zhang,&nbsp;Hongjun Gao,&nbsp;Chushu Liao,&nbsp;Fen Yuan,&nbsp;Zhen Huang,&nbsp;Xisha Huan,&nbsp;Shan Feng,&nbsp;Fangfang Chen,&nbsp;Ping Lei","doi":"10.1016/j.htct.2026.106491","DOIUrl":"10.1016/j.htct.2026.106491","url":null,"abstract":"<div><h3>Objectives</h3><div>Plasma transfusion is commonly used in intensive care units, often for non-bleeding indications despite limited evidence. This study aimed to evaluate the association between plasma transfusions and in-hospital mortality among critically ill patients.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using data from 282 adult intensive care unit patients who received transfusion therapy between January and December 2020. Patients were grouped by their exposure to plasma transfusion and further by the transfusion volume. First, multivariable Cox regression coupled with propensity score matching was used to control for baseline confounders and quantify the independent association of plasma transfusion with in-hospital mortality. Subsequently, Cox models and Kaplan-Meier survival curves were employed to elucidate the dose-response relationship between transfusion volume and mortality risk, with additional subgroup analyses.</div></div><div><h3>Results</h3><div>In the unadjusted analysis, plasma transfusion was significantly associated with increased in-hospital mortality (Hazard ratio = 4.199; 95% confidence interval: 2.53–6.97; p-value &lt;0.001). This association persisted after propensity score matching adjusted for key confounders (Hazard ratio = 3.271; 95% confidence interval: 1.30–8.21; p-value = 0.012). Kaplan-Meier survival analysis demonstrated significantly lower survival probabilities in the transfusion group (log-rank p-value &lt;0.05). Furthermore, a dose-dependent relationship was revealed: mortality risk increased at higher volumes, reaching statistical significance at &gt;800 mL (Hazard ratio = 4.09; 95% confidence interval: 1.19–14.04; p-value = 0.025). Subgroup analysis indicated that the elevated risk was particularly pronounced among patients who concurrently received red blood cell transfusions.</div></div><div><h3>Conclusion</h3><div>Plasma transfusion is independently and dose-dependently associated with increased mortality in critically ill patients, particularly when used without clear indications. These findings support a restrictive, evidence-based approach, emphasizing correction of underlying coagulopathy over prophylactic transfusion. Strict adherence to guidelines and an individualized risk-benefit assessment are essential to improve patient safety.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106491"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148311071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MPL mutations are over-represented in patients with dual driver-mutated myeloproliferative neoplasms: an Irish cohort study","authors":"Laura Kearney,&nbsp;Claire Andrews,&nbsp;Rachel Brodie,&nbsp;Ezzat Elhassadi,&nbsp;Helen Enright,&nbsp;Kamal Fadalla,&nbsp;Michael Fay,&nbsp;Catherine Flynn,&nbsp;Anne Fortune,&nbsp;Andrew Hodgson,&nbsp;Senthil Kumar,&nbsp;Kanthi Perera,&nbsp;Jeremy Sargent,&nbsp;Liam Smyth,&nbsp;Stephen E. Langabeer","doi":"10.1016/j.htct.2026.106495","DOIUrl":"10.1016/j.htct.2026.106495","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106495"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148427732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of intravenous ferric derisomaltose in Brazilian patients with iron deficiency anemia","authors":"Lauro Augusto Caetano Leite,&nbsp;Gisele dos Santos Barros,&nbsp;Thomas Azevedo do Carmo,&nbsp;Rodolfo Delfini Cançado","doi":"10.1016/j.htct.2026.106501","DOIUrl":"10.1016/j.htct.2026.106501","url":null,"abstract":"<div><h3>Background</h3><div>Iron deficiency anemia remains a major global health concern, especially among women, children, and people with chronic illnesses. Oral iron therapy is the standard treatment, but it is often limited by gastrointestinal side effects or poor absorption. Intravenous ferric derisomaltose is a newer formulation that allows high-dose, rapid iron replenishment with a favorable safety profile. This study aimed to assess the effectiveness and safety of intravenous ferric derisomaltose in patients with iron deficiency anemia who could not tolerate or did not respond to oral iron.</div></div><div><h3>Methods</h3><div>This was a prospective, open-label, single-center trial conducted in São Paulo, Brazil. Adult patients (≥18 years) with iron deficiency anemia received 1 or 2 infusions of intravenous ferric derisomaltose (up to 1000 mg per infusion). Hematologic and iron parameters were measured at baseline, Week 4, and Week 8. Safety outcomes included adverse events and serum phosphate levels.</div></div><div><h3>Results</h3><div>Thirty patients were treated with 25 requiring a second infusion. Significant increases in hemoglobin, serum ferritin, transferrin saturation, and reticulocyte hemoglobin content were seen at both time points. By Week 8, 81% achieved a hemoglobin increase ≥2 <em>g</em>/dL, and 54% achieved an increase of ≥3 <em>g</em>/dL. Four (8%) mild adverse events occurred and three patients (10%) experienced transient, asymptomatic hypophosphatemia, which resolved without intervention.</div></div><div><h3>Conclusion</h3><div>This study contributes to the growing evidence supporting the use of intravenous ferric derisomaltose as a safe and effective alternative for distinct populations with iron deficiency anemia. In this real-world clinical setting, the treatment is effective for treating patients with iron deficiency, providing rapid hematologic recovery with a favorable safety profile.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106501"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13393526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of survival among children with Burkitt lymphoma treated at a single center in Tanzania: a retrospective cohort study","authors":"Aika A. Shoo,&nbsp;Advera I. Ngazia,&nbsp;Nahya S. Masoud,&nbsp;Shakilu Jumanne,&nbsp;James J. Yahaya","doi":"10.1016/j.htct.2026.106496","DOIUrl":"10.1016/j.htct.2026.106496","url":null,"abstract":"<div><h3>Background</h3><div>Despite improvements in the management of patients with Burkitt lymphoma, the survival rate in low- and middle-income countries remains poor. This study aimed to determine the predictors of 18-month overall survival among children with Burkitt lymphoma.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted at the Pediatric Oncology unit of Muhimbili National Hospital in Dar-es-salaam, Tanzania. The study included a cohort of 123 children who were diagnosed with Burkitt lymphoma from January 2012 to December 2017. Predictors of mortality were assessed using Cox regression analysis. A two-tailed p-value &lt;0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>The median age of the patients was seven years and the majority 61.8% (76/123) were males. Abdominal presentation was the most common tumor site in 39% (48/123). The 18-month overall survival rate was 54.0%. Key predictors of mortality included human immunodeficiency virus (HIV) infection (adjusted Hazard ratio [aHR] = 5.12; 95% CI: 1.39–19.0; p &lt; 0.01) and elevated lactate dehydrogenase levels (&gt;500 U/L; aHR = 2.50; 95% CI: 1.14–14.71; p = 0.03).</div></div><div><h3>Conclusion</h3><div>Most patients presented with abdominal Burkitt lymphoma. Despite the tumor's high chemosensitivity, treatment response in this cohort was marginal, characterized by moderate overall survival and low event-free survival. HIV infection and elevated lactate dehydrogenase levels were significant predictors of mortality. Improving outcomes will require optimized early diagnosis, HIV screening, and rigorous patient follow-up.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"48 3","pages":"Article 106496"},"PeriodicalIF":1.5,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}